Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a new 2026 Sales and Distribution Framework Agreement with China Resources Kelun (Sichuan) Medicine Limited, under which China Resources Kelun will act as a non-exclusive distributor of certain of the company’s commercialized pharmaceutical products in mainland China from 1 January 2026 to 31 December 2028. As China Resources Kelun is an associate of director Liu Sichuan, the arrangement constitutes a continuing connected transaction under Hong Kong listing rules, triggering reporting and announcement requirements but remaining exempt from independent shareholders’ approval, thereby formalizing a key distribution channel while maintaining regulatory compliance for related-party dealings.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a PRC-incorporated biopharmaceutical company listed in Hong Kong, focusing on the commercialization and distribution of pharmaceutical products in mainland China. The company operates through sales to distribution partners and downstream distributors and end customers across the Chinese healthcare market.
Average Trading Volume: 616,548
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.63B
See more data about 6990 stock on TipRanks’ Stock Analysis page.